HCW Biologics Inc. entered into a Securities Purchase Agreement on July 29, 2026, to raise approximately $1.6 million in gross proceeds through the sale of 618,682 units at $2.585 per unit. Each unit consists of one share of common stock or a pre-funded warrant and one common stock purchase warrant exercisable for up to 618,682 shares at an exercise price of $2.585 per share. The issuance of the warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Proceeds will fund clinical development activities, including trials for HCW9302 and IND-enabling studies for HCW11-018b and HCW11-040. The company also entered into a Registration Rights Agreement to file an S-1 within 15 trading days of closing. HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.
